CL2014000818A1 - Compuestos derivados de (fenil/heteroaril)-etinil-(piridin/pirimidin/piridazin)-acetamida, moduladores del receptor metabotropico de glutamato; procedimiento de preparacion; composicion farmaceutica; y su uso en esquizofrenia, enfermedades cognitivas, sindrome x-fragil o autismo - Google Patents

Compuestos derivados de (fenil/heteroaril)-etinil-(piridin/pirimidin/piridazin)-acetamida, moduladores del receptor metabotropico de glutamato; procedimiento de preparacion; composicion farmaceutica; y su uso en esquizofrenia, enfermedades cognitivas, sindrome x-fragil o autismo

Info

Publication number
CL2014000818A1
CL2014000818A1 CL2014000818A CL2014000818A CL2014000818A1 CL 2014000818 A1 CL2014000818 A1 CL 2014000818A1 CL 2014000818 A CL2014000818 A CL 2014000818A CL 2014000818 A CL2014000818 A CL 2014000818A CL 2014000818 A1 CL2014000818 A1 CL 2014000818A1
Authority
CL
Chile
Prior art keywords
autism
pyridazine
schizophrenia
pyrimidin
ethynyl
Prior art date
Application number
CL2014000818A
Other languages
English (en)
Inventor
Georg Jaeschke
Lothar Lindemann
Antonio Ricci
Daniel Rueher
Eric Vieira
Heinz Stadler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2014000818A1 publication Critical patent/CL2014000818A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22Nitrogen and oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Liquid Crystal (AREA)
CL2014000818A 2011-10-07 2014-04-03 Compuestos derivados de (fenil/heteroaril)-etinil-(piridin/pirimidin/piridazin)-acetamida, moduladores del receptor metabotropico de glutamato; procedimiento de preparacion; composicion farmaceutica; y su uso en esquizofrenia, enfermedades cognitivas, sindrome x-fragil o autismo CL2014000818A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11184257 2011-10-07

Publications (1)

Publication Number Publication Date
CL2014000818A1 true CL2014000818A1 (es) 2014-09-05

Family

ID=47016705

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014000818A CL2014000818A1 (es) 2011-10-07 2014-04-03 Compuestos derivados de (fenil/heteroaril)-etinil-(piridin/pirimidin/piridazin)-acetamida, moduladores del receptor metabotropico de glutamato; procedimiento de preparacion; composicion farmaceutica; y su uso en esquizofrenia, enfermedades cognitivas, sindrome x-fragil o autismo

Country Status (31)

Country Link
US (1) US8530472B2 (es)
EP (1) EP2763969B1 (es)
JP (1) JP5840794B2 (es)
KR (1) KR101656966B1 (es)
CN (1) CN103857658B (es)
AR (1) AR088765A1 (es)
BR (1) BR112014008078A2 (es)
CA (1) CA2847096A1 (es)
CL (1) CL2014000818A1 (es)
CO (1) CO6900142A2 (es)
CR (1) CR20140093A (es)
CY (1) CY1117212T1 (es)
DK (1) DK2763969T3 (es)
EA (1) EA024993B1 (es)
ES (1) ES2556796T3 (es)
HK (1) HK1193596A1 (es)
HR (1) HRP20160144T1 (es)
HU (1) HUE026626T2 (es)
IL (1) IL231439A (es)
IN (1) IN2014CN02477A (es)
MX (1) MX354414B (es)
PE (1) PE20141555A1 (es)
PL (1) PL2763969T3 (es)
PT (1) PT2763969E (es)
RS (1) RS54511B1 (es)
SG (1) SG11201401307WA (es)
SI (1) SI2763969T1 (es)
TW (1) TWI458710B (es)
UA (1) UA110995C2 (es)
WO (1) WO2013050460A1 (es)
ZA (1) ZA201402068B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA113223C2 (xx) * 2012-08-13 2016-12-26 Арилетинілпіримідини
PE20150733A1 (es) * 2012-10-18 2015-05-17 Hoffmann La Roche Derivados de etinilo como moduladores de la actividad del receptor mglur5
KR102035048B1 (ko) 2015-06-03 2019-10-22 에프. 호프만-라 로슈 아게 에틴일 유도체

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002008205A1 (en) * 2000-07-24 2002-01-31 Krenitsky Pharmaceuticals, Inc. Substituted 5-alkynyl pyrimidines having neurotrophic activity
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
US7776869B2 (en) 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
EP1809620B1 (en) 2004-11-04 2010-12-29 Addex Pharma SA Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
PL1863818T3 (pl) * 2005-03-23 2010-08-31 Hoffmann La Roche Pochodne acetylenylo-pirazolo-pirymidyny jako antagoniści MGLUR2
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
SG185285A1 (en) 2007-06-03 2012-11-29 Univ Vanderbilt Benzamide mglur5 positive allosteric modulators and methods of making and using same
US8853392B2 (en) 2007-06-03 2014-10-07 Vanderbilt University Benzamide mGluR5 positive allosteric modulators and methods of making and using same
TW201010984A (en) 2008-07-29 2010-03-16 Boehringer Ingelheim Int 5-alkynyl-pyrimidines
US8389536B2 (en) * 2009-10-27 2013-03-05 Hoffmann-La Roche Inc. Positive allosteric modulators (PAM)

Also Published As

Publication number Publication date
JP2014531466A (ja) 2014-11-27
KR20140069303A (ko) 2014-06-09
NZ621583A (en) 2015-11-27
WO2013050460A1 (en) 2013-04-11
PE20141555A1 (es) 2014-10-30
US20130090347A1 (en) 2013-04-11
EP2763969A1 (en) 2014-08-13
HRP20160144T1 (hr) 2016-03-11
PL2763969T3 (pl) 2016-04-29
ES2556796T3 (es) 2016-01-20
TWI458710B (zh) 2014-11-01
CA2847096A1 (en) 2013-04-11
ZA201402068B (en) 2015-03-25
CO6900142A2 (es) 2014-03-20
CY1117212T1 (el) 2017-04-05
CN103857658B (zh) 2016-08-24
US8530472B2 (en) 2013-09-10
PT2763969E (pt) 2016-02-02
AU2012320509B2 (en) 2016-10-13
AU2012320509A8 (en) 2016-10-20
RS54511B1 (en) 2016-06-30
MX2014003636A (es) 2014-06-04
SG11201401307WA (en) 2014-06-27
KR101656966B1 (ko) 2016-09-12
CN103857658A (zh) 2014-06-11
DK2763969T3 (en) 2015-12-14
HUE026626T2 (en) 2016-06-28
SI2763969T1 (sl) 2016-01-29
EP2763969B1 (en) 2015-11-25
TW201321356A (zh) 2013-06-01
EA024993B1 (ru) 2016-11-30
AR088765A1 (es) 2014-07-02
CR20140093A (es) 2014-05-07
UA110995C2 (uk) 2016-03-10
MX354414B (es) 2018-03-05
JP5840794B2 (ja) 2016-01-06
EA201490720A1 (ru) 2014-07-30
HK1193596A1 (zh) 2014-09-26
BR112014008078A2 (pt) 2017-04-11
IL231439A0 (en) 2014-04-30
AU2012320509A1 (en) 2014-03-13
IL231439A (en) 2016-04-21
IN2014CN02477A (es) 2015-06-19

Similar Documents

Publication Publication Date Title
DK3418281T3 (da) Pyrazolo[1,5-a]pyrimidiner, der er anvendelige som inhibitorer af atr-kinase til behandling af cancersygdomme
CR20140259A (es) Compuestos novedosos de benzopirano, composiciones y usos de los mismos
DK3238709T3 (da) Forbedrede parenterale formuleringer af lipofile farmaceutiske midler og fremgangsmåder til fremstilling og anvendelse af samme
CL2014001280A1 (es) Compuestos derivados de 4-fenil -piridinas sustituidas, moduladores del receptor de nk1; procedimiento de preparacion; composicion farmaceutica; y su uso en el tratamiento de la emesis, disfuncion vesical, depresion o ansiedad
DK3632919T3 (da) Farmaceutiske sammensætninger omfattende imidazothiadiazol- og imidazopyrazinderivater som proteaseaktiverede receptor 4-(par4)- hæmmere til behandling af blodpladeaggregering
DK3590928T3 (da) Pyrimidinderivater til behandling af virusinfektioner
CO7131375A2 (es) Uracilos sustituidos bicíclicamente y uso de los mismos
CL2015003444A1 (es) Compuestos de 3,4 dihidroisoquinolin-2(1h)-ilo
DK2718270T3 (da) Sammensætninger og fremgangsmåder til fremstillingen af pyrimidin- og pyridinforbindelser med btk-hæmmende aktivitet
CL2013001891A1 (es) Compuestos heterociclicos fusionados; composicion farmaceutica y uso en el tratamiento de la degeneracion macular asociada con la edad.
BR112015000420A2 (pt) composto, composição farmacêutica, e, uso de um composto
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
DK2462116T3 (da) Fremgangsmåde til fremstillingen af farmaceutisk aktive forbindelser
BR112014005669A2 (pt) composto, composição farmacêutica e uso de um composto
BR112013011448A2 (pt) composto, composição farnmacêutica, e, uso do composto
DK2773648T3 (da) Farmaceutiske forbindelser til anvendelse i behandlingen af clostridium difficile-infektion
CO6970609A2 (es) Composición farmacéutica y métodos de uso de derivados de 4-pregenen-11ß-17-21-triol-3,20-diona
BR112014003567A2 (pt) composto, uso de um composto, e, composição farmacêutica
DK3040336T3 (da) Forbindelser til brug i behandling af TYK2 Kinase-medierede tilstande
CL2014000849A1 (es) Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas.
BR112014013177A2 (pt) composto, composição farmacêutica e uso de um composto
CL2014000819A1 (es) Compuestos heterociclicos derivados de etinilo, moduladores alostericos mglur5; proceso de preparacion; composicion farmaceutica; uso en la prevencion o el tratamiento de esquizofrenia, enfermedades cognitivas, sindrome de la x fragil o autismo.
PL2919801T3 (pl) Stabilna kompozycja farmaceutyczna białka fuzyjnego TNFR:FC etanerceptu
CL2013003056A1 (es) Compuestos derivados de (fenil o piridin)-etinil-(piridin o pirimidin) sustituido; composición farmacéutica que los comprende; proceso de preparación de esto; y su uso en el tratamiento de la esquizofrenia o enfermedades cognitivas.
BR112014013178A2 (pt) composto, composição farmacêutica e uso de um composto